Eleutherococcus Senticosus Inhibits Rankl-Induced Osteoclast Formation By Attenuating The Nf-Kappa B And Mapks Signaling Pathway

Natural plant derived eleutherococcus senticosus (ES) has potential therapeutic and preventative effects on treating bone metabolism diseases such as: arthritis and osteoporosis. However, the mechanisms of ES effects on the osteoclastogenesis remains to be investigated. The current study is the first time to explored the effect of ES on RANKL mediated marrow derived macrophages (BMMs) and mice macrophage RAW 264.7 cells in vitro. Here, we found ES can significantly decrease RANKL-induced osteoclast differentiation and bone resorption compared with the control in dose dependent manner and showed no cytotoxicity. ES also downregulated the expression of osteoclastic genes such as TRAP and OSCAR. Moreover, ES markedly inhibited the phosphorylation of early signaling pathway such as NF-kappa B and MAPKs activity. Furthermore, ES extract significantly decreased the expression of osteoclast key transcriptor c-Fos/NFATc-1. Our results collectively demonstrating that as a natural compound, ES may serve as a useful drug in the prevention of bone resorption disease.